These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25345428)

  • 1. Peramivir pharmacokinetics in a patient receiving continuous veno-venous hemodiafiltration during the 2009 H1N1 influenza A pandemic.
    Bentley ML; Hollistera AS; Hansenb AC; Smith JA; Cain JS
    Int J Clin Pharmacol Ther; 2014 Dec; 52(12):1105-11. PubMed ID: 25345428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peramivir pharmacokinetics in two critically ill adults with 2009 H1N1 influenza A concurrently receiving continuous renal replacement therapy.
    Bazan JA; Bauer KA; Hollister AS; Shidham G; Firstenberg MS; Reed EE; Mangino JE; Goff DA
    Pharmacotherapy; 2010 Oct; 30(10):1016-20. PubMed ID: 20874039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peramivir clearance in continuous renal replacement therapy.
    Thomas B; Hollister AS; Muczynski KA
    Hemodial Int; 2010 Jul; 14(3):339-40. PubMed ID: 20491974
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetic assessment of peramivir in a hospitalized adult undergoing continuous venovenous hemofiltration.
    Scheetz MH; Griffith MM; Ghossein C; Hollister AS; Ison MG
    Ann Pharmacother; 2011 Dec; 45(12):e64. PubMed ID: 22116989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and safety of intravenous peramivir, neuraminidase inhibitor of influenza virus, in healthy Japanese subjects.
    Saisho Y; Ishibashi T; Fukuyama H; Fukase H; Shimada J
    Antivir Ther; 2017; 22(4):313-323. PubMed ID: 27805571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influenza viral load and peramivir kinetics after single administration and proposal of regimens for peramivir administration against resistant variants.
    Sato M; Ito M; Suzuki S; Sakuma H; Takeyama A; Oda S; Watanabe M; Hashimoto K; Miyazaki K; Kawasaki Y; Hosoya M
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1643-9. PubMed ID: 25547357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection.
    Sugaya N; Kohno S; Ishibashi T; Wajima T; Takahashi T
    Antimicrob Agents Chemother; 2012 Jan; 56(1):369-77. PubMed ID: 22024821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between in vivo antiviral activity and pharmacokinetic parameters of peramivir in influenza virus infection model in mice.
    Kodama M; Yoshida R; Hasegawa T; Izawa M; Kitano M; Baba K; Noshi T; Seki T; Okazaki K; Tsuji M; Kanazu T; Kamimori H; Homma T; Kobayashi M; Sakoda Y; Kida H; Sato A; Yamano Y
    Antiviral Res; 2014 Sep; 109():110-5. PubMed ID: 24997412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peramivir: an intravenous neuraminidase inhibitor for the treatment of 2009 H1N1 influenza.
    Mancuso CE; Gabay MP; Steinke LM; Vanosdol SJ
    Ann Pharmacother; 2010; 44(7-8):1240-9. PubMed ID: 20516360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of extracorporeal membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of oseltamivir carboxylate in critically ill patients with pandemic (H1N1) influenza.
    Lemaitre F; Luyt CE; Roullet-Renoleau F; Nieszkowska A; Zahr N; Corvol E; Fernandez C; Antignac M; Farinotti R; Combes A
    Ther Drug Monit; 2012 Apr; 34(2):171-5. PubMed ID: 22354159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment.
    Barroso L; Treanor J; Gubareva L; Hayden FG
    Antivir Ther; 2005; 10(8):901-10. PubMed ID: 16430195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peramivir and its use in H1N1 influenza.
    Castillo R; Holland LE; Boltz DA
    Drugs Today (Barc); 2010 Jun; 46(6):399-408. PubMed ID: 20571608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftolozane/Tazobactam Pharmacokinetics in a Critically Ill Adult Receiving Continuous Renal Replacement Therapy.
    Bremmer DN; Nicolau DP; Burcham P; Chunduri A; Shidham G; Bauer KA
    Pharmacotherapy; 2016 May; 36(5):e30-e33. PubMed ID: 27012450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation.
    Eyler RF; Heung M; Pleva M; Sowinski KM; Park PK; Napolitano LM; Mueller BA
    Pharmacotherapy; 2012 Dec; 32(12):1061-9. PubMed ID: 23208833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peramivir for Influenza A and B Viral Infections: A Pharmacokinetic Case Series.
    Cies JJ; Moore WS; Enache A; Chopra A
    Pharmacotherapy; 2019 Nov; 39(11):1060-1065. PubMed ID: 31514223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peramivir for the treatment of influenza.
    Shetty AK; Peek LA
    Expert Rev Anti Infect Ther; 2012 Feb; 10(2):123-43. PubMed ID: 22339187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of intravenous peramivir in the airway epithelial lining fluid of healthy volunteers.
    Funatsu Y; Tasaka S; Asami T; Namkoong H; Fujiwara H; Iketani O; Yagi K; Kimizuka Y; Ishii M; Nishimura T; Ogata H; Iwata S; Betsuyaku T; Hasegawa N
    Antivir Ther; 2016; 21(7):621-625. PubMed ID: 27694694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation.
    Mariat C; Venet C; Jehl F; Mwewa S; Lazarevic V; Diconne E; Fonsale N; Carricajo A; Guyomarc'h S; Vermesch R; Aubert G; Bidault R; Bertrand JC; Zeni F
    Crit Care; 2006 Feb; 10(1):R26. PubMed ID: 16507147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of peramivir in healthy volunteers and influenza patients.
    Matsuo Y; Ishibashi T; Hollister AS; Wajima T
    Antimicrob Agents Chemother; 2015 Nov; 59(11):6755-62. PubMed ID: 26282420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single intramuscular injection of neuraminidase inhibitor peramivir demonstrates antiviral activity against novel pandemic A/California/04/2009 (H1N1) influenza virus infection in mice.
    Bantia S; Kellogg D; Parker C; Upshaw R; Ilyushina NA; Babu YS
    Antiviral Res; 2011 Apr; 90(1):17-21. PubMed ID: 21316393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.